繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
Mangoceuticals | 10-Q: Q3 2024 Earnings Report
Mangoceuticals | 10-Q: Q3 2024 Earnings Report
Mangoceuticals | 10-Q:2024財年三季報
牛牛AI助理已提取核心訊息
Mangoceuticals, Inc. reported financial results for the quarter ended September 30, 2024. Revenue for the quarter was $133,368, a decrease from $245,160 in the same period the previous year. Operating expenses totaled $1,840,745, slightly down from $1,944,049 in the prior year's quarter. The company experienced a net loss of $1,999,694, compared to a net loss of $1,799,460 in the same quarter of the previous year. The decrease in revenue and net loss was attributed to delays in marketing activities due to the migration to a new telehealth platform. For the nine months ended September 30, 2024, the company had a net loss of $6,758,630, with revenues of $510,626, an increase from $487,119 in the same period last year. The company's cash and cash equivalents stood at $73,912, down from $739,006 at the end...Show More
Mangoceuticals, Inc. reported financial results for the quarter ended September 30, 2024. Revenue for the quarter was $133,368, a decrease from $245,160 in the same period the previous year. Operating expenses totaled $1,840,745, slightly down from $1,944,049 in the prior year's quarter. The company experienced a net loss of $1,999,694, compared to a net loss of $1,799,460 in the same quarter of the previous year. The decrease in revenue and net loss was attributed to delays in marketing activities due to the migration to a new telehealth platform. For the nine months ended September 30, 2024, the company had a net loss of $6,758,630, with revenues of $510,626, an increase from $487,119 in the same period last year. The company's cash and cash equivalents stood at $73,912, down from $739,006 at the end of the previous year. Mangoceuticals also reported a working deficit of $1.3 million and an accumulated deficit of $17,985,966 as of September 30, 2024. The company highlighted the need for additional funding to support operations over the next 12 months and may seek additional funding through equity or debt financings. Mangoceuticals also mentioned a strategic review process to evaluate potential transactions that could result in a change of control or a significant change in operations.
Mangoceuticals 公司報告了截至2024年9月30日的季度財務業績。本季度的營業收入爲$133,368,較前一年同期的$245,160有所減少。營業費用總計$1,840,745,略低於前一年同期的$1,944,049。公司淨損失爲$1,999,694,而去年同季度的淨損失爲$1,799,460。營業收入和淨損失的減少歸因於由於遷移至新的遠程醫療平台而導致營銷活動延遲。截至2024年9月30日爲止的九個月,公司的淨損失爲$6,758,630,營業收入爲$510,626,較去年同期的$487,119有所增加。公司的現金及現金等價物爲$73,912,低於上一年底的$739,006。Man...展開全部
Mangoceuticals 公司報告了截至2024年9月30日的季度財務業績。本季度的營業收入爲$133,368,較前一年同期的$245,160有所減少。營業費用總計$1,840,745,略低於前一年同期的$1,944,049。公司淨損失爲$1,999,694,而去年同季度的淨損失爲$1,799,460。營業收入和淨損失的減少歸因於由於遷移至新的遠程醫療平台而導致營銷活動延遲。截至2024年9月30日爲止的九個月,公司的淨損失爲$6,758,630,營業收入爲$510,626,較去年同期的$487,119有所增加。公司的現金及現金等價物爲$73,912,低於上一年底的$739,006。Mangoceuticals 還報告了 $130萬 的工作透支和截至2024年9月30日的累積透支爲 $17,985,966。公司強調了需要額外資金支持未來12個月的運營,並可能通過股權或債務融資尋求額外資金。Mangoceuticals 還提及了一項戰略審查流程,以評估可能導致控制權變更或運營方式顯著變化的潛在交易。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了